Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery

Title: Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery

Volume: 7 Issue: 3

Author(s): Javier A. Montero, Jose M Ruiz-Moreno and Maria E. Correa

Affiliation:

Keywords: Diabetic retinopathy, Proliferative diabetic retinopathy, Diabetic macular edema, VEGF, Bevacizumab, Ranibizumab, Pegaptanib, Bevasiranib, VEGF trap, Vitrectomy, Laser photocoagulation, Phacoemulsification, Glaucoma surgery

Abstract: The use of intravitreal anti vascular endothelial growth factor (anti-VEGF) drugs such as pegaptanib, ranibizumab and bevacizumab has been widely reported to treat complications such as macular edema and rubeosis. During the past few years they have also been used as an adjuvant therapy to reduce intraocular bleeding during vitrectomy in eyes with proliferative diabetic retinopathy as well as to reduce the occurrence of vitreous haemorrhages in vitrectomized eyes and facilitate glaucoma surgery.

In this paper we review the use of anti VEGF drugs in the surgical management of diabetic retinopathy related complications.

Cite this article as:

A. Montero Javier, M Ruiz-Moreno Jose and E. Correa Maria, Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery, Current Diabetes Reviews 2011; 7 (3) . https://dx.doi.org/10.2174/157339911795843104